{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:46:49Z","timestamp":1793040409074,"version":"4.5.0"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>N-acetylcysteine (NAC) is a key precursor of glutathione (GSH), the lung\u2019s principal antioxidant. First developed as a mucolytic, NAC is now recognized for broader antioxidant, anti-inflammatory, immunomodulatory, and anti-biofilm effects, prompting its use as an adjuvant in treatment of chronic respiratory conditions. This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An expert working group (EWG) comprising ten pulmonologists and a multidisciplinary drafting committee reviewed data from\n                      <jats:italic>in vitro<\/jats:italic>\n                      , mechanistic, animal and observational studies, randomized trials, reviews and meta-analyses for role of NAC in respiratory diseases. Eight respiratory conditions: stable COPD, acute exacerbations of COPD (AECOPD), tuberculosis (TB), and anti-tubercular drug\u2013induced liver injury (AT-DILI), non-cystic fibrosis bronchiectasis, cystic fibrosis (CF), bacterial and viral infections, interstitial lung disease (ILD), and asthma were studied and discussed. A modified Delphi process was conducted to establish expert consensus on the role of NAC in each of these conditions. Consensus was defined as \u226570% agreement on predefined statements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Experts agreed that NAC is useful as an adjunct in COPD especially chronic bronchitis phenotypes mainly for preventing exacerbations at 600 mg twice daily. During AECOPD, low dose NAC may aid recovery. In TB and AT-DILI, NAC is safe, lowers oxidative stress and may limit lung damage. In non-CF bronchiectasis, NAC may reduce exacerbations in frequent exacerbators. In CF, NAC improves lung function, mucociliary clearance, and disrupts biofilms. NAC is useful in bacterial and viral infections but data for ILDs and asthma does not support routine use. NAC was consistently rated safe and well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC\u2019s antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. It is a proven adjunctive therapy for COPD, bronchiectasis, and cystic fibrosis. While promising for TB and respiratory infections, further evidence is required. Its efficacy in asthma and ILDs remains uncertain. These findings guide clinical practice while highlighting research priorities to fully establish NAC\u2019s therapeutic potential in respiratory medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1810363","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:34Z","timestamp":1777872694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR)"],"prefix":"10.3389","volume":"13","author":[{"given":"Monica","family":"Barne","sequence":"first","affiliation":[{"name":"Chest Research and Training Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuragauri","family":"Shevade","sequence":"additional","affiliation":[{"name":"Chest Research and Training Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathi","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Institute of Pulmocare and Research","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devasahayam J.","family":"Christopher","sequence":"additional","affiliation":[{"name":"Christian Medical College Vellore","place":["Vellore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Nair","sequence":"additional","affiliation":[{"name":"Government Medical College","place":["Thiruvananthapuram, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"Poona Hospital and Research Center","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Halder","sequence":"additional","affiliation":[{"name":"College of Medicine and JNM Hospital, West Bengal University of Health Sciences","place":["Kalyani, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam","family":"Vora","sequence":"additional","affiliation":[{"name":"BSES Brahma Kumaris\u2019 Global Hospital & Vora Clinic","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Khanna","sequence":"additional","affiliation":[{"name":"School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Swarnakar","sequence":"additional","affiliation":[{"name":"Getwell Hospital and Research Institute","place":["Nagpur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Chhajed","sequence":"additional","affiliation":[{"name":"Nanavati Max Super Speciality Hospital and Lilavati Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamurugan","family":"Santhalingam","sequence":"additional","affiliation":[{"name":"ACS Medical College and Hospital, Dr. M.G.R. Educational and Research Institute University","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Nair","sequence":"additional","affiliation":[{"name":"Chest Research and Training Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Salvi","sequence":"additional","affiliation":[{"name":"Chest Research and Training Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1164\/arrd.1964.90.5.721","article-title":"The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine.","volume":"90","author":"Sheffner","year":"1964","journal-title":"Am Rev Respir Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(77)90612-2","article-title":"Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine.","volume":"2","author":"Prescott","year":"1977","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine.","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/aid.1992.8.209","article-title":"N-acetylcysteine: a new approach to anti-HIV therapy.","volume":"8","author":"Roederer","year":"1992","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s002280050140","article-title":"Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial.","volume":"50","author":"Akerlund","year":"1996","journal-title":"Eur J Clin Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1056\/NEJM200007203430304","article-title":"Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.","volume":"343","author":"Tepel","year":"2000","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2013a double-blind, randomized, placebo-controlled trial.","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review.","volume":"55","author":"Deepmal, Slattery","year":"2015","journal-title":"Neurosci Biobehav Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia.","volume":"54","author":"Yolland","year":"2020","journal-title":"Aust N Z J Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13898","DOI":"10.1111\/and.13898","article-title":"Antioxidant effects of N-acetylcysteine on the male reproductive system: a systematic review.","volume":"53","author":"Ghafarizadeh","year":"2021","journal-title":"Andrologia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1515\/jbcpp-2020-0107","article-title":"N-acetyl-cysteine as adjuvant therapy in female infertility: a systematic review and meta-analysis.","volume":"32","author":"Devi","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9949453","DOI":"10.1155\/2021\/9949453","article-title":"N-acetylcysteine: a review of clinical usefulness (an old drug with new tricks).","volume":"2021","author":"Schwalfenberg","year":"2021","journal-title":"J Nutr Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.resp.2013.10.010","article-title":"Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg\/day NAC in moderate to severe COPD patients: a pilot study.","volume":"191","author":"Sinojia","year":"2014","journal-title":"Respir Physiol Neurobiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17476348.2018.1495562","article-title":"Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.","volume":"12","author":"Calzetta","year":"2018","journal-title":"Expert Rev Respir Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599815601394","article-title":"Clinical consensus statement development manual.","volume":"153","author":"Rosenfeld","year":"2015","journal-title":"Otolaryngol Head Neck Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2471\/BLT.21.286870","article-title":"Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis.","volume":"100","author":"Jarhyan","year":"2022","journal-title":"Bull World Health Organ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41533-024-00378-7","article-title":"A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.","volume":"34","author":"Salvi","year":"2024","journal-title":"NPJ Prim Care Respir Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1001\/jama.2023.2065","article-title":"Airway-occluding mucus plugs and mortality in patients with chronic obstructive Pulmonary disease.","volume":"329","author":"Diaz","year":"2023","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2147\/COPD.S504065","article-title":"Impact of airway-occluding mucus plugs on mortality in patients with COPD according to disease severity: a subset analysis of data from COPDGene.","volume":"20","author":"Rogliani","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0021-8707(67)90090-1","article-title":"An evaluation of the effect of nebulized N-acetylcysteine on sputum consistency.","volume":"39","author":"Hirsch","year":"1967","journal-title":"J Allergy."},{"key":"B21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00606554","article-title":"A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.","volume":"9","author":"Grassi","year":"1976","journal-title":"Eur J Clin Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/030006058401200312","article-title":"Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study.","volume":"12","author":"Jackson","year":"1984","journal-title":"J Int Med Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1183\/09031936.93.01040351","article-title":"Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.","volume":"1","author":"Rasmussen","year":"1988","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000029447","article-title":"N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.","volume":"66","author":"Pela","year":"1999","journal-title":"Respiration."},{"key":"B25","unstructured":"Bachh\n              A.\n            \n          \n          Effect of Oral N-acetylcysteine in COPD-A Randomised Controlled Trial.\n          \n          2007"},{"key":"B26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/thx.40.11.832","article-title":"Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee.","volume":"40","author":"Macfarlane","year":"1985","journal-title":"Thorax"},{"key":"B27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.03.00063402","article-title":"N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.","volume":"21","author":"Gerrits","year":"2003","journal-title":"Eur Respir J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial.","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.rmed.2008.11.003","article-title":"Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.","volume":"103","author":"Schermer","year":"2009","journal-title":"Respir Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1378\/chest.09-0421","article-title":"Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.","volume":"136","author":"Stav","year":"2009","journal-title":"Chest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","article-title":"Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.","volume":"23","author":"Hurst","year":"2022","journal-title":"Respir Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1378\/chest.12-2357","article-title":"High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.","volume":"144","author":"Tse","year":"2013","journal-title":"Chest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1378\/chest.13-2784","article-title":"Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.","volume":"146","author":"Tse","year":"2014","journal-title":"Chest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.rmed.2018.12.014","article-title":"Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study.","volume":"147","author":"Papi","year":"2019","journal-title":"Respir Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"OC16","DOI":"10.7860\/JCDR\/2016\/23668.8980","article-title":"N-acetylcysteine combined with home based physical activity: effect on health related quality of life in stable COPD patients- a randomised controlled trial.","volume":"10","author":"Salve","year":"2016","journal-title":"J Clin Diagn Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.18203\/2319-2003.ijbcp20161518","article-title":"Effects of administration of oral n-acetylcysteine on oxidative stress in chronic obstructive pulmonary disease patients in rural population.","volume":"5","author":"Kale","year":"2016","journal-title":"Int J Basic Clin Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1038\/s41467-024-51079-1","article-title":"Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S2213-2600(13)70294-7","article-title":"N-acetylcysteine in COPD may be beneficial, but for whom?","volume":"2","author":"Cazzola","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S2213-2600(14)70054-2","article-title":"N-acetylcysteine for COPD: the evidence remains inconclusive.","volume":"2","author":"Turner","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1183\/16000617.00002215","article-title":"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.","volume":"24","author":"Cazzola","year":"2015","journal-title":"Eur Respir Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.","volume":"16","author":"Stey","year":"2000","journal-title":"Eur Respir J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/copd.2006.1.4.425","article-title":"Role of N-acetylcysteine in the management of COPD.","volume":"1","author":"Sadowska","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/copd.2006.1.2.99","article-title":"The role for N-acetylcysteine in the management of COPD.","volume":"1","author":"Dekhuijzen","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/15412550600977361","article-title":"N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.","volume":"3","author":"Sutherland","year":"2006","journal-title":"COPD."},{"key":"B46","doi-asserted-by":"publisher","first-page":"CD001287","DOI":"10.1002\/14651858.CD001287.pub5","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.","volume":"5","author":"Poole","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"CD001287","DOI":"10.1002\/14651858.CD001287.pub6","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.","volume":"5","author":"Poole","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"17534666231158563","DOI":"10.1177\/17534666231158563","article-title":"The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis.","volume":"17","author":"Huang","year":"2023","journal-title":"Ther Adv Respir Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.arbres.2024.03.010","article-title":"N-acetylcysteine treatment in chronic obstructive Pulmonary disease (COPD) and chronic bronchitis\/pre-COPD: distinct meta-analyses.","volume":"60","author":"Papi","year":"2024","journal-title":"Arch Bronconeumol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2025.3159","article-title":"Mucus production and chronic obstructive pulmonary disease, a possible treatment target: zooming in on N-acetylcysteine.","author":"Baraldi","year":"2025","journal-title":"Monaldi Arch Chest Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European respiratory society\/american thoracic society guideline.","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S2213-2600(24)00413-2","article-title":"GOLD COPD report: 2025 update.","volume":"13","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1761","DOI":"10.21037\/jtd.2019.05.10","article-title":"Chronic obstructive pulmonary disease classification, phenotypes and risk assessment.","volume":"11","author":"Manian","year":"2019","journal-title":"J Thorac Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1513\/pats.200512-125SF","article-title":"Pathophysiology of exacerbations of chronic obstructive pulmonary disease.","volume":"3","author":"Papi","year":"2006","journal-title":"Proc Am Thorac Soc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12931-016-0500-y","article-title":"Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.","volume":"18","author":"Cazzola","year":"2017","journal-title":"Respir Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00044011-200525060-00005","article-title":"High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.","volume":"25","author":"Zuin","year":"2005","journal-title":"Clin Drug Investig."},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejcdt.2013.02.012","article-title":"High dose N-acetyl cysteine improves inflammatory response and outcome in patients with COPD exacerbations.","volume":"62","author":"Mahmoud","year":"2013","journal-title":"Egypt J Chest Dis Tuberculosis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e6073","DOI":"10.7759\/cureus.6073","article-title":"N-acetylcysteine in the management of acute exacerbation of chronic obstructive Pulmonary disease.","volume":"11","author":"Ansari","year":"2019","journal-title":"Cureus."},{"key":"B59","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000238595","article-title":"Serum, sputum and bronchial concentrations of erythromycin in chronic bronchitis after single and multiple treatments with either Propionate-N-Acetylcysteinate or stearate erythromycin.","volume":"34","author":"Ricevuti","year":"1988","journal-title":"Chemotherapy."},{"key":"B60","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1055\/s-2002-36122","article-title":"[N-acetylcystein in the therapy of chronic bronchitis].","volume":"56","author":"Reichenberger","year":"2002","journal-title":"Pneumologie."},{"key":"B61","first-page":"65","article-title":"[Multicenter, double-blind study of oral acetylcysteine vs. placebo].","volume":"111","author":"Brocard","year":"1980","journal-title":"Eur J Respir Dis Suppl."},{"key":"B62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2466-4-13","article-title":"Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].","volume":"4","author":"Black","year":"2004","journal-title":"BMC Pulm Med."},{"key":"B63","unstructured":"A Randomized, Double-Blind, Placebo Controlled, Parallel Groups Study on Efficacy and Safety of nac 600 mg Daily and nac 1200 mg Daily as Mucolytic Agent in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation.\n          \n          2010"},{"key":"B64","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00508-014-0692-4","article-title":"N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.","volume":"127","author":"Ayfer Aytemur","year":"2015","journal-title":"Wien Klin Wochenschr."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6564","DOI":"10.21037\/apm-21-1138","article-title":"Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease.","volume":"10","author":"Jiang","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"220141","DOI":"10.1183\/16000617.0141-2022","article-title":"Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis.","volume":"32","author":"Papadopoulou","year":"2023","journal-title":"Eur Respir Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12866-016-0872-7","article-title":"N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.","volume":"16","author":"Amaral","year":"2016","journal-title":"BMC Microbiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3389\/fimmu.2018.02069","article-title":"The synergistic effects of the glutathione precursor, NAC and first-line antibiotics in the granulomatous response against Mycobacterium tuberculosis.","volume":"9","author":"Teskey","year":"2018","journal-title":"Front Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.micpath.2015.11.006","article-title":"Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.","volume":"93","author":"Khameneh","year":"2016","journal-title":"Microb Pathog."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1703","DOI":"10.1128\/AAC.01703-20","article-title":"The promises and limitations of N- acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.","volume":"65","author":"Vilch\u00e8ze","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"602589","DOI":"10.3389\/fimmu.2020.602589","article-title":"Adjunct N-acetylcysteine treatment in hospitalized patients with HIV-associated tuberculosis dampens the oxidative stress in peripheral blood: results from the RIPENACTB study trial.","volume":"11","author":"Safe","year":"2021","journal-title":"Front Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/2229-3485.210450","article-title":"N-acetylcysteine as an add-on to directly observed therapy short-I therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study.","volume":"8","author":"Mahakalkar","year":"2017","journal-title":"Perspect Clin Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e0235381","DOI":"10.1371\/journal.pone.0235381","article-title":"Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: an open-label, randomized, phase II trial (RIPENACTB Study).","volume":"15","author":"Safe","year":"2020","journal-title":"PLoS One."},{"key":"B74","doi-asserted-by":"publisher","first-page":"EVIDoa2300332","DOI":"10.1056\/EVIDoa2300332","article-title":"Adjunctive N-acetylcysteine and lung function in pulmonary tuberculosis.","volume":"3","author":"Wallis","year":"2024","journal-title":"NEJM Evid."},{"key":"B75","doi-asserted-by":"publisher","first-page":"106379","DOI":"10.1016\/j.jinf.2024.106379","article-title":"N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis.","volume":"90","author":"Mapamba","year":"2025","journal-title":"J Infect."},{"key":"B76","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.2147\/JIR.S542396","article-title":"N-acetylcysteine as a potential immunomodulator in Tuberculosis: evidence of IL-2 elevation in a pilot study.","volume":"18","author":"Yudhawati","year":"2025","journal-title":"J Inflamm Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1191\/096032700674230830","article-title":"Isoniazid- and rifampicin-induced oxidative hepatic injury\u2013protection by N-acetylcysteine.","volume":"19","author":"Attri","year":"2000","journal-title":"Hum Exp Toxicol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3748\/wjg.v12.i2.287","article-title":"Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats.","volume":"12","author":"Rana","year":"2006","journal-title":"World J Gastroenterol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1097\/MEG.0b013e32833aa11b","article-title":"Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.","volume":"22","author":"Baniasadi","year":"2010","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5829\/idosi.wjms.2015.12.4.10114","article-title":"Efficacy of N-acetylcysteine on prevention of antituberculosis drug-induced hepatotoxicity.","volume":"12","author":"Farazi","year":"2015","journal-title":"World J Med Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijtb.2022.05.012","article-title":"A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life.","volume":"70","author":"Sukumaran","year":"2023","journal-title":"Indian J Tuberc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/ajhp\/zxaa202","article-title":"Possible role for acetylcysteine as a treatment for acute liver failure secondary to antitubercular medication use.","volume":"77","author":"Fox","year":"2020","journal-title":"Am J Health Syst Pharm."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e3377","DOI":"10.1093\/cid\/ciaa1255","article-title":"A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury.","volume":"73","author":"Moosa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1780","DOI":"10.1093\/cid\/ciaa1683","article-title":"N-acetyl cysteine in antitubercular drug-induced liver injury: in search of homogenous evidence.","volume":"73","author":"Hampannavar","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20473\/jr.v6-I.1.2020.27-34","article-title":"The role of N-acetyl sistein in pulmonary tuberculosis.","volume":"6","author":"Yudhawati","year":"2020","journal-title":"JR."},{"key":"B86","doi-asserted-by":"publisher","first-page":"5907839","DOI":"10.1155\/2020\/5907839","article-title":"N-acetyl cysteine as an adjunct in the treatment of tuberculosis.","volume":"2020","author":"Ejigu","year":"2020","journal-title":"Tuberc Res Treat."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/antiox11112298","article-title":"Impact of N-acetyl cysteine (NAC) on tuberculosis (TB) patients-a systematic review.","volume":"11","author":"Mapamba","year":"2022","journal-title":"Antioxidants."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","article-title":"Bronchiectasis in India: results from the European multicentre bronchiectasis audit and research collaboration (EMBARC) and respiratory research network of India registry.","volume":"7","author":"Dhar","year":"2019","journal-title":"Lancet Glob Health."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European respiratory society guidelines for the management of adult bronchiectasis.","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British thoracic society guideline for bronchiectasis in adults.","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax."},{"key":"B91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-019-1042-x","article-title":"Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial.","volume":"20","author":"Qi","year":"2019","journal-title":"Respir Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.pupt.2023.102283","article-title":"Evaluation of high dose N- acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: a randomised placebo-controlled pilot study.","volume":"84","author":"Jayaram","year":"2024","journal-title":"Pulm Pharmacol Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.21037\/jtd-2025-1159","article-title":"What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.","volume":"17","author":"Oscullo","year":"2025","journal-title":"J Thorac Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2501126","DOI":"10.1183\/13993003.01126-2025","article-title":"European respiratory society clinical practice guideline for the management of adult bronchiectasis.","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur Respir J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24966\/PMRR-0177\/100002","article-title":"Cystic fibrosis in India: past, present and future.","volume":"1","author":"Kabra","year":"2015","journal-title":"Pulmonary Med Respir Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12881-020-01153-4","article-title":"NGS-based expanded carrier screening for genetic disorders in North Indian population reveals unexpected results - a pilot study.","volume":"21","author":"Singh","year":"2020","journal-title":"BMC Med Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4103\/cmi.cmi_150_23","article-title":"Diagnosis of cystic fibrosis beyond childhood in india.","volume":"22","author":"Medhi","year":"2024","journal-title":"Current Medical Issues."},{"key":"B98","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ph15020217","article-title":"N-acetylcysteine (NAC) and its role in clinical practice management of cystic fibrosis (CF): a review.","volume":"15","author":"Guerini","year":"2022","journal-title":"Pharmaceuticals."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/thoraxjnl-2021-217576","article-title":"Bacterial biofilms predominate in both acute and chronic human lung infections.","volume":"77","author":"Kolpen","year":"2022","journal-title":"Thorax."},{"key":"B100","doi-asserted-by":"publisher","first-page":"106372","DOI":"10.1016\/j.ijantimicag.2021.106372","article-title":"Disruption of biofilms and killing of Burkholderia cenocepacia from cystic fibrosis lung using an antioxidant-antibiotic combination therapy.","volume":"58","author":"Aiyer","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/antibiotics10101176","article-title":"Effect of N-acetylcysteine in combination with antibiotics on the biofilms of three cystic fibrosis pathogens of emerging importance.","volume":"10","author":"Aiyer","year":"2021","journal-title":"Antibiotics."},{"key":"B102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1440-1754.1982.tb01978.x","article-title":"Controlled trial of oral N-acetylcysteine in cystic fibrosis.","volume":"18","author":"Mitchell","year":"1982","journal-title":"Aust Paediatr J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/BF00441781","article-title":"A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis.","volume":"144","author":"Ratjen","year":"1985","journal-title":"Eur J Pediatr."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3282911","DOI":"10.1183\/09031936.93.01020161","article-title":"The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia.","volume":"1","author":"Stafanger","year":"1988","journal-title":"Eur Respir J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1183\/09031936.93.02030234","article-title":"N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility.","volume":"2","author":"Stafanger","year":"1989","journal-title":"Eur Respir J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.","volume":"103","author":"Tirouvanziam","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B107","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/2047-783x-14-8-352","article-title":"A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis.","volume":"14","author":"Dauletbaev","year":"2009","journal-title":"Eur J Med Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.","volume":"14","author":"Conrad","year":"2015","journal-title":"J Cyst Fibros."},{"key":"B109","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jcf.2014.09.015","article-title":"The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection \u2013 a pilot study.","volume":"14","author":"Skov","year":"2015","journal-title":"J Cyst Fibros."},{"key":"B110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7573\/dic.2025-7-7","article-title":"N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care.","volume":"14","author":"Benedetti","year":"2025","journal-title":"Drugs Context."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3390\/ijms20143423","article-title":"Biofilms: the microbial;protective clothing; in extreme environments.","volume":"20","author":"Yin","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2180-10-140","article-title":"N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.","volume":"10","author":"Zhao","year":"2010","journal-title":"BMC Microbiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1916-0216-43-20","article-title":"In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media.","volume":"43","author":"Lea","year":"2014","journal-title":"J Otolaryngol Head Neck Surg."},{"key":"B114","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","article-title":"The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections.","volume":"117","author":"Blasi","year":"2016","journal-title":"Respir Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/jac\/dkaa093","article-title":"The effect of N-acetylcysteine in a combined antibiofilm treatment against antibiotic-resistant Staphylococcus aureus.","volume":"75","author":"Manoharan","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B116","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/bja\/aef169","article-title":"Alveolar and serum oxidative stress in ventilator-associated pneumonia.","volume":"89","author":"Duflo","year":"2002","journal-title":"Br J Anaesth."},{"key":"B117","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4067\/S0716-97602013000200013","article-title":"Relationship between severity of adult community-acquired pneumonia and impairment of the antioxidant defense system.","volume":"46","author":"Castillo","year":"2013","journal-title":"Biol Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3889\/oamjms.2016.040","article-title":"Characteristic of the oxidative stress in blood of patients in dependence of community-acquired pneumonia severity.","volume":"4","author":"Muravlyova","year":"2016","journal-title":"Open Access Maced J Med Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e13087","DOI":"10.1097\/MD.0000000000013087","article-title":"N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial.","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine."},{"key":"B120","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/2045-9912.229599","article-title":"Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: a randomized, double blind, placebo-controlled clinical trial.","volume":"8","author":"Sharafkhah","year":"2018","journal-title":"Med Gas Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/039463201202500123","article-title":"Recurrent acute rhinosinusitis: a single blind clinical study of N-Acetylcysteine vs ambroxol associated to corticosteroid therapy.","volume":"25","author":"Macchi","year":"2012","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2399\/jmu.2014001005","article-title":"Effect of N-acetylcysteine for the treatment of otitis media with effusion.","volume":"4","author":"Boztepe","year":"2014","journal-title":"J Med Updates."},{"key":"B123","doi-asserted-by":"publisher","first-page":"70","DOI":"10.33762\/bsurg.2019.164517","article-title":"The role of n-acetylcysteine in the treatment of otitis media with effusion.","volume":"25","author":"Fadhel","year":"2019","journal-title":"Basrah J Surg."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-119x.1000182","article-title":"The effects of N-acetyl cysteine on nasal mucociliary clearance in healthy volunteers: a randomized, double-blind and placebo-controlled study.","volume":"5","author":"Homayoun Elahi","year":"2015","journal-title":"Otolaryngology."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4172\/2324-8785.1000272","article-title":"Effect of N- acetylcysteine on nasal mucociliary clearance in chronic sinusitis.","volume":"5","author":"Yadav","year":"2016","journal-title":"J Otol Rhinol."},{"key":"B126","first-page":"44","article-title":"Oxidative stress and low glutathione in common ear, nose, and throat conditions: a systematic review.","volume":"22","author":"Asher","year":"2016","journal-title":"Altern Ther Health Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.bcp.2009.08.025","article-title":"N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.","volume":"79","author":"Geiler","year":"2010","journal-title":"Biochem Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2011.05.014","article-title":"N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV).","volume":"82","author":"Mata","year":"2011","journal-title":"Biochem Pharmacol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2014.06.013","article-title":"N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.","volume":"22","author":"Zhang","year":"2014","journal-title":"Int Immunopharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1183\/09031936.97.10071535","article-title":"Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.","volume":"10","author":"De Flora","year":"1997","journal-title":"Eur Respir J."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jcbmr.2016.13","article-title":"N-acetylcysteine: an old drug with variable Anti-influenza properties.","volume":"2","author":"Casanova","year":"2016","journal-title":"J Controversies Biomed Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.aimed.2020.07.006","article-title":"The effects of N-acetyl cysteine on acute viral respiratory infections in humans: a rapid review.","volume":"7","author":"Schloss","year":"2020","journal-title":"Adv Integr Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00408-021-00465-3","article-title":"Use of thiols in the treatment of COVID-19: current Evidence.","volume":"199","author":"Cazzola","year":"2021","journal-title":"Lung."},{"key":"B134","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15586\/ijfs.v37i1.2787","article-title":"N-acetylcysteine as a promising treatment for COVID-19: a comprehensive meta-analysis of systemic manifestations and clinical outcomes.","volume":"37","author":"Saleh","year":"2025","journal-title":"Ital. J. Food Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e0271665","DOI":"10.1371\/journal.pone.0271665","article-title":"Incidence, prevalence, and national burden of interstitial lung diseases in India: estimates from two studies of 3089 subjects.","volume":"17","author":"Dhooria","year":"2022","journal-title":"PLoS One."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis.","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1465-9921-10-101","article-title":"Lung function in idiopathic pulmonary fibrosis\u2013extended analyses of the IFIGENIA trial.","volume":"10","author":"Behr","year":"2009","journal-title":"Respir Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.","volume":"370","author":"Martinez","year":"2014","journal-title":"N Engl J Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis.","volume":"192","author":"Oldham","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12890-018-0599-3","article-title":"N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.","volume":"18","author":"Oldham","year":"2018","journal-title":"BMC Pulm Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","article-title":"Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"4","author":"Behr","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B143","first-page":"5660","article-title":"Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis.","volume":"14","author":"Zhang","year":"2022","journal-title":"Am J Transl Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e3629","DOI":"10.1097\/MD.0000000000003629","article-title":"Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine."},{"key":"B145","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12890-020-1121-2","article-title":"Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.","volume":"20","author":"Shi","year":"2020","journal-title":"BMC Pulm Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3892\/etm.2019.7579","article-title":"Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: an updated systematic review and meta-analysis.","volume":"18","author":"Feng","year":"2019","journal-title":"Exp Ther Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e6555","DOI":"10.5867\/medwave.2016.6555","article-title":"Is N-acetylcysteine effective in the treatment of pulmonary fibrosis?","volume":"16","author":"Jeldres Pulgar","year":"2016","journal-title":"Medwave."},{"key":"B148","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.rmed.2016.01.011","article-title":"The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis.","volume":"112","author":"Hamzeh","year":"2016","journal-title":"Respir Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"00528","DOI":"10.1183\/23120541.00528-2021","article-title":"Prevalence, time trends and treatment practices of asthma in India: the global asthma network study.","volume":"8","author":"Singh","year":"2022","journal-title":"ERJ Open Res."},{"key":"B150","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1006\/phrs.2001.0917","article-title":"Effectiveness of oral N -acetylcysteine in a rat experimental model of asthma.","volume":"45","author":"Blesa","year":"2002","journal-title":"Pharmacol Res."},{"key":"B151","first-page":"26417226","article-title":"Preventive effect of N-acetylcysteine in a mouse model of steroid resistant acute exacerbation of asthma.","volume":"12","author":"Eftekhari","year":"2013","journal-title":"EXCLI J."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1080\/02770903.2020.1781166","article-title":"Protective effects of N-acetylcysteine on a chemical-induced murine model of asthma.","volume":"58","author":"Song","year":"2021","journal-title":"J Asthma."},{"key":"B153","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s11033-020-05466-8","article-title":"Correlation between oxidative stress and NF-\u03baB signaling pathway in the obesity-asthma mice.","volume":"47","author":"Liu","year":"2020","journal-title":"Mol Biol Rep."},{"key":"B154","first-page":"20683104","article-title":"Effects of N-acetylcysteine on asthma exacerbation.","volume":"9","author":"Aliyali","year":"2010","journal-title":"Iran J Allergy Asthma Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/toxsci\/kfu040","article-title":"Anti-oxidant N-acetylcysteine diminishes diesel exhaust-induced increased airway responsiveness in person with airway hyper-reactivity.","volume":"139","author":"Carlsten","year":"2014","journal-title":"Toxicol Sci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/bmj.287.6396.876","article-title":"Asthma associated with N-acetylcysteine infusion and paracetamol poisoning: report of two cases.","volume":"287","author":"Ho","year":"1983","journal-title":"Br Med J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40264-020-01026-y","article-title":"Safety of N-acetylcysteine at high doses in chronic respiratory diseases: a review.","volume":"44","author":"Calverley","year":"2021","journal-title":"Drug Saf."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:38Z","timestamp":1777872698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":157,"alternative-id":["10.3389\/fmed.2026.1810363"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1810363","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1810363"}}